BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.25 (+2.49%)

Stability Price

Overvalued by 97.91%

Company Metrics

  • P/E 0
  • P/S 14.98
  • P/B 11.49
  • EPS -0.5
  • Cash ROIC -229.93%
  • Cash Ratio 1.26
  • Dividend 0 / 0%
  • Avg. Vol. 945,817.00
  • Shares 73.34M
  • Market Cap. 753.89M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


BioCryst Pharmaceuticals, Inc. Short Interest Update
Money Flow Index - 7 hours ago
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), A reduction of 393,718 shares or 4.2% was observed in the short interest of BioCryst Pharmaceuticals, Inc. The interest on November 13,2015 came in at 9,081,465 shares and as per the average daily trading ...
A Reversal for BioCryst Pharmaceuticals, Inc. Is Not Near. The Stock Declines ... - Voice Chronicle
Top Stories: BioCryst Pharmaceuticals (NASDAQ:BCRX), First Northwest Bancorp ... - Benchmark Monitor
Company Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Rally 4.26%
News Watch International - Nov 23, 2015
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose by 4.26% in the past week and 14.11% for the last 4 weeks.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) Stock Price Up as Sentiment Improves
OctaFinance.com - Nov 20, 2015
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) hedge funds sentiment increased to 2.29 in Q2 2015. Its up 0.94, from 1.35 in 2015Q1.
Here's Why Shares of BioCryst Pharmaceuticals, Inc. Are Falling Today
Motley Fool - Oct 8, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that specializes in the development of small molecular drugs, sank by over 20% today on heavy volume.
BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results - TheStreet.com
3 Biotech Stocks Are Getting Crushed: BioCryst Pharmaceuticals, Inc. (NASDAQ ... - Wall Street Point
Price Target Update on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
News Watch International - Nov 19, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): 7 analysts have set the short term price target of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) at $16.29. The standard deviation of short term price target has been estimated at $5.25, implying that the ...
How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Analysts Are Bearish? - FinancialMagazin.com
Update: Analysts Rate Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) a 1 ... - The Bulletin
Durham's BioCryst cuts $45 million deal with Australian firm
Triangle Business Journal - Jun 17, 2015
Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq: BCRX) licensed its recently approved flu treatment Rapivap in a deal that could bring the company $45 million plus sales royalties.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has licensed RAPIVAB (peramivir ... - Inside Trade
BioCryst Pharma licenses flu med to CSL Limited (BCRX) - Seeking Alpha
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Update
Investor Newswire - Nov 19, 2015
Sell-side brokerage firm are predicting that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will post earnings per share of $-0.2 for the current fiscal quarter.
Technical and Fundamental Report on BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
Street Report - Nov 12, 2015
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $9.47, down by -7.25%, with a volume of 858,732 shares against an average volume for the last 3 months of ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update - News Watch International
BioCryst Pharma (BCRX) is Downgraded by BofA/Merrill to Underperform - Money Flow Index
BioCryst Pharmaceuticals, Inc. Analyst Rating Update
American Trade Journal - Nov 4, 2015
Analysts at Zacks have given a short term rating of hold on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) with a rank of 3. The company has received an average rating of 1.75 from 8 brokerage firms.
NASDAQ:BCRX Stockholder Notice: Investigation of BioCryst Pharmaceuticals, Inc ... - Empowered News
Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX): Can Biocryst ... - The Bulletin
Revenue Update on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
News Watch International - Nov 6, 2015
BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) announced the earnings results for Fiscal Year 2015 and Q3. The results came in during Pre-market on Nov 5, 2015.
BioCryst Pharma (BCRX) Announces Quarterly Earnings Results, Reports EPS of ... - Money Flow Index
BioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Thursday - Dakota Financial News